This product comprises a CRISPR/Cas9-edited polyclonal knockout cell population of human 786-O renal adenocarcinoma cells, engineered for loss-of-function of the ECE1 gene through targeted gene disruption. The CRISPR/Cas9-mediated knockout approach generates a heterogeneous polyclonal pool, enabling functional studies without clonal isolation and minimizing clone-specific artifacts. This polyclonal format offers a robust and reproducible system for investigating the collective impact of ECE1 ablation on cellular phenotypes.
The parental 786-O cell line is a well-established model of renal cell carcinoma (RCC), originally derived from a primary clear cell carcinoma. These cells represent a widely used in vitro system for studying the molecular mechanisms underlying kidney cancer, including tumor growth, drug resistance, and metastatic progression.
ECE1 encodes an endothelin-converting enzyme that proteolytically processes big endothelin-1 to mature endothelin-1, a potent vasoconstrictor and mitogen. Endothelin-1 signals through endothelin A (ETA) and B (ETB) receptors, which couple to G??q/11 and activate phospholipase C?? (PLC??), generating inositol trisphosphate (IP3) and diacylglycerol (DAG). This leads to calcium mobilization and protein kinase C (PKC) activation, converging on the MAPK/ERK cascade via MAPK1/3 (ERK1/2). ECE1 activity is regulated by upstream factors such as hypoxia, TGF-??, and HIF-1??, and its product endothelin-1 promotes downstream effects including cell proliferation, survival, and angiogenesis. The zinc-dependent metalloprotease also interacts directly with its substrate big endothelin-1 and endothelin receptors.
In the context of 786-O renal cell carcinoma cells, ECE1-mediated endothelin-1 production likely contributes to tumor progression by driving autocrine and paracrine signaling loops that enhance proliferation, angiogenesis, and metastatic potential. Disruption of ECE1 in this polyclonal knockout model provides a valuable tool to dissect the role of endothelin signaling in RCC pathobiology, particularly given the known association between endothelin-1 overexpression and poor prognosis in renal cancer. This model allows researchers to assess the dependency of 786-O cells on ECE1 activity for key malignant traits.
The ECE1 Knockout 786-O Polyclonal Cells are suitable for a range of advanced biomedical research applications, including functional studies of endothelin receptor signaling, tumor angiogenesis assays (e.g., tube formation), and drug target validation for ECE1 inhibitors. Representative experimental workflows include Western blotting and RT-qPCR to confirm ECE1 disruption, endothelin-1 ELISA to quantify ligand production, cell proliferation (MTT/BrdU) and migration/invasion assays to assess phenotypic changes, apoptosis detection (Annexin V/PI), phospho-ERK analysis, calcium flux measurements, and transcriptome-wide RNA-seq profiling. This knockout model thus serves as a critical platform for investigating ECE1-dependent mechanisms in renal cell carcinoma and for preclinical evaluation of potential therapeutics. For further information or technical support, please contact Ascent Research.
